Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Redeye Investor Forum Malmö (March 2022)
14 slides from Cantargia Ab's conference presentation, March 2022
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Göran Forsberg, CEO March 2022 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – The IL1RAP company
Cantargia – The IL1RAP company FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET • Five Phase I/II trials, with positive interim data in pancreatic cancer and NSCLC • Differentiated by broad MOA and unique binding properties • Synergistic with established therapies PLATFORM WITH BROAD PO
Slide 4: Cantargia – Save lives and create value through IL1RAP
Cantargia – Save lives and create value through IL1RAP Potentially more effective treatment against novel target in clinically validated pathway First in class platform technology against novel target Well-financed to build a broad, diversified pipeline Right team and clear plan to position our proj
Slide 5: Advancing PDAC development to phase 2/3
Advancing PDAC development to phase 2/3 PanCAN’s Precision Promise℠ adaptive clinical trial platform designed together with the FDA Nadunolimab selected for inclusion → 15 leading US clinical centers - additional sites planned → Patients randomized to receive nadunolimab with gemcitabine and nab-pac
Slide 6: Positive interim data in pancreatic cancer
Positive interim data in pancreatic cancer Nadunolimab combination with Gem/Abraxane in 1st line (Dec 2021), n=33: → 27% response rate with durable responses, two patients still on treatment → Pseudoprogression-like response in 5 (15%) patients predict long PFS → Promising PFS (7.2 mo) and OS (12.7
Slide 7: Safety profile is manageable and supports MOA
Safety profile is manageable and supports MOA CANFOUR Gem/Abraxane FOLFIRINOX Nadunolimab/ Grade 3 or higher AEs (von Hoff 2013) (Conroy 2011) Gem/Abraxane N=421 N=171 N=36 Neutropenia 38% 67% 46% → G-CSF is an approved therapy to counteract neutropenia; G-CSF Febrile neutropenia 3% 17%
Slide 8: Combination strategy in NSCLC – Promising efficacy
Combination strategy in NSCLC – Promising efficacy Nadunolimab combination with Gem/Cis in 1st line: → 13 of 27 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (ORR 48% vs historical control data of 22- 28%) → No major s
Slide 9: CIRIFOUR – Broadening into IO combinations
CIRIFOUR – Broadening into IO combinations → First arm (15 pts): Combination with pembrolizumab in patients no longer responding to PD-(L)1 therapy (NSCLC, HNSCC, malignant melanoma and bladder cancer) → Very good safety, only one treatment related grade 3 AE (febrile neutropenia); 5 pts on treatmen
Slide 10: Cantargia – Save lives and create value through IL1RAP
Cantargia – Save lives and create value through IL1RAP 10
Slide 11: CAN10 – New asset within autoimmunity/inflammation
CAN10 – New asset within autoimmunity/inflammation → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on unmet medical need in syste
Slide 12: CAN10 – Unique properties in preclinical disease models
CAN10 – Unique properties in preclinical disease models Myocarditis - Treatment from day 7 Left Ventricular Ejection Fraction 1.1 ** Ratio of baseline 1.0 * mCAN10 Control mCAN10 0.9 Anti-IL-1β Control Anti-IL-1β 0.8 Vehicle 0.7 0 10 20 30 40 Day Systemic sclerosis model CLINICAL TRIAL STRATEGY UNDE
Slide 13: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents SEK 559.4 M (~$59M) at end Q4 2021 Current owners (31 Dec 2021) → Operating expenses SEK 370.3 M (~$39M) in Q1-Q4 2021 • R&D is 95% of operating expenses Swedbank Robur Funds 9.6% • 26 full-time employees 4th AP fun
Slide 14: Several upcoming value inflection points
Several upcoming value inflection points Newsflow over next 6-9 months Nadunolimab (CAN04) → New results for PDAC, NSCLC and Keytruda combination (CANFOUR, CIRIFOUR) → Phase 2/3 Precision Promise (PDAC) → New preclinical and translational results → New clinical trials (Interim results, safety) • CAP